On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Ariad sells off a share of Iclusig for a shot at $200M in R&D cash

Ariad Pharmaceuticals has inked a deal with PDL BioPharma, trading a long-term royalty on its only marketed drug in exchange for money to develop another.

ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with PDL BioPharma

Funding to support initiation of first-line study of brigatinib in ALK+ NSCLC and commercial launch readiness for brigatinib CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2015-- ARIAD Pharmaceuticals,...

MannKind settles up with note holders in stock/note deal; Loxo surges on patient response;

@FierceBiotech: ICYMI yesterday: Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer. Article | Follow @FierceBiotech @JohnCFierce: I'm putting together a half-day...

The big question for Gilead: Who are you going to buy?

Last night Gilead execs basked in the glow of market-bending sales numbers, backed by the continuing megasuccess of its two hep C drugs, Harvoni and Sovaldi, which racked up close to $5 billion in revenue for the second quarter. So naturally analysts want to know how they plan to spend the cash.

ERYTECH Announces Plans to Conduct Registered Initial Public Offering in the United States

LYON, France--()--Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative 'tumor...

Foresite Capital reloads with a $450M biotech venture fund

Venture investor Foresite Capital closed a $450 million new fund, its largest ever, and is setting out to find the next generation of promising drug developers.

Foresite Capital Closes $450 Million Fund III to Finance Transformative, Late-stage Healthcare Companies

SAN FRANCISCO & NEW YORK--()--Foresite Capital, a healthcare growth equity firm, today announced the closing of Foresite Capital Fund III, which was oversubscribed and closed with...

Sprint Bioscience Enters into Collaboration with Bayer Healthcare on Tumor Metabolism Program

STOCKHOLM--()--Sprint Bioscience AB: (STO:SPRINT) Sprint Bioscience AB (publ) (Sprint Bioscience) and Bayer HealthCare (Bayer) have entered into a collaboration and license agreement for...

Sanofi's diabetes combo clears a clinical hurdle in a race with Novo Nordisk

Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.